Oncimmune Holdings PLC Exercise of Options and Total Voting Rights (0792W)
August 13 2020 - 5:38AM
UK Regulatory
TIDMONC
RNS Number : 0792W
Oncimmune Holdings PLC
13 August 2020
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Exercise of Options & Total Voting Rights
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, today announces that following an exercise
of options over ordinary shares by an employee of the Company (the
"Exercise"), application has been made to the London Stock Exchange
for 1,500 new ordinary shares of GBP0.01 each in the Company
("Ordinary Shares") to be admitted to trading on AIM on or around
the 19 August 2020 ("Admission").
The Exercise was made under the 2016 Share Option Plan. The new
Ordinary Shares will rank pari passu with the Company's existing
Ordinary Shares.
Total Voting Rights
The Company advises that, following Admission, the Company's
issued share capital will be 63,540,975 Ordinary Shares all with
voting rights. The above figure of 63,540,975 may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FCA's
Disclosure and Transparency Rules.
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Chris Lee
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Our intimate understanding of the human immune system enables us
to harness its sophisticated response to disease to detect cancer
earlier and to support the development of better therapies.
The key to improving cancer survival is early detection and
better selection for therapy. As a company, we are driven by our
passion to improve cancer survival and give people extra time.
Oncimmune's immunodiagnostic test, EarlyCDT, can detect and help
identify cancer on average four years earlier than standard
clinical diagnosis.
The unique combination of our core technology and understanding
of the immune system, powers our ImmunoINSIGHTS service; a
proprietary platform that enables life science organisations to
optimise drug development and delivery, leading to more effective,
targeted as well as safer treatments for patients.
Oncimmune was founded in 2002 and launched its platform
diagnostic technology in 2009, followed by the launch of its first
commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over
200,000 tests have been performed for patients worldwide. EarlyCDT
Lung was also used in what is believed to be the largest randomised
controlled trial for the early detection of lung cancer using
biomarkers, the successful National Health Service (NHS) Early
detection of Cancer of the Lung ("ECLS") trial of 12,209 high-risk
smokers in Scotland. This trial demonstrated that EarlyCDT Lung
reduced the incidence of patients with late-stage lung cancer or
unclassified presentation at diagnosis, compared to standard
clinical practice.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, has a discovery research centre in Dortmund,
Germany and a partner representative office in Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRSFWFSDESSEDA
(END) Dow Jones Newswires
August 13, 2020 06:38 ET (10:38 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024